Abstract:Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Research has shown that lysosome-mediated autophagy is up regulated in response to various stimuli such as hypoxia, nutrient limitation, and drug-induced cytotoxic stress. In cancer progression, autophagy plays a cytoprotective role by generating needed nutrients or by eliminating damaged cellular components. Although autophagy has been recognized as a critical tumor cell survival mechanism and much is known about the induction and early steps of autophagy, the molecule(s) which control the later stages of autophagic progression are less clear. Previously, we have identified lysosomal-associated protein transmembrane 4b (LAPTM4B) as an amplified and over-expressed gene in breast cancer that is associated with de novo resistance to anthracycline chemotherapy and increased risk of distant metastatic recurrence. We reported that LAPTM4B overexpression alters intracellular trafficking of anthracyclines by retaining the drug in the cytoplasmic compartment thereby limiting drug-induced DNA damage in the nucleus. However, how this protein contributes to tumor cell survival in the setting of other types of stress requires further investigation. In the present studies, we used fluorescence microscopy to confirm LAPTM4B protein distribution in the lysosomal compartment of cells. Depletion of this gene results in increased lysosome membrane permeability as demonstrated by release from lysosomes of low to intermediate molecular weight dextran. Furthermore, we find that over expression of LAPTM4B renders cells resistant to apoptosis when placed in nutrient-free media suggesting a possible role of LAPTM4B in promoting lysosome-mediated autophagy. We induced autophagy by serum starvation in BT549 breast cancer cells with or without depletion of LAPTM4B. Autophagic progression was monitored by immunofluorescence for the autophagosome marker, LC3, and for degradation of P62 as evidence of autolysosome maturation. We find that depletion of LAPTM4B interrupted autophagosome maturation to autolysosomes as indicated by appearance of LC3 but absence of P62 degradation. In addition, we observed aggregation of autophagosomes in LAPTM4B-depleted cells and caspase activation, indicative of apoptosis. These events are a recognized sequela of blocked autophagic maturation. In summary, we find that ablation of LAPTM4B results in increased lysosome membrane permeability, inhibition of autophagosome-lysosome fusion, and toxic accumulation of autophagasomes triggering cell death. These results suggest a novel function for the amplified cancer gene, LAPTM4B, in promoting the later stages of autophagic maturation and tumor resistance to apoptosis-inducing stress. Targeting LAPTM4B may provide a new strategy to prevent metabolic adaptation of cancer cells by abolishing the cytoprotective effects of autophagy and increasing drug therapy efficacy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3772. doi:10.1158/1538-7445.AM2011-3772

Ablation of ATG4B Suppressed Autophagy and Activated AMPK for Cell Cycle Arrest in Cancer Cells

ATG4B Promotes Colorectal Cancer Growth Independent of Autophagic Flux.

Abstract LB-128: High Throughput Screening Kinase Activators of Atg4B for Cancer Therapy.

Targeting ATG4 in Cancer Therapy

ATG4B and ATG4A loss result in two-stage cell cycle defects in pancreatic ductal adenocarcinoma cells

BMP4 Promotes Hepatocellular Carcinoma Proliferation by Autophagy Activation Through JNK1-mediated Bcl-2 Phosphorylation

AKT-mediated Phosphorylation of ATG4B Impairs Mitochondrial Activity and Enhances the Warburg Effect in Hepatocellular Carcinoma Cells

Targeting Atg4B for cancer therapy: Chemical mediators

Knockdown ATG4C Inhibits Gliomas Progression and Promotes Temozolomide Chemosensitivity by Suppressing Autophagic Flux

Discovery of a small molecule targeting autophagy via ATG4B inhibition and cell death of colorectal cancer cells in vitro and in vivo.

MST4 Phosphorylation of ATG4B Regulates Autophagic Activity, Tumorigenicity, and Radioresistance in Glioblastoma

Silencing of ATG4D Suppressed Proliferation and Enhanced Cisplatin-Induced Apoptosis in Hepatocellular Carcinoma Through Akt/Caspase-3 Pathway.

CtBP maintains cancer cell growth and metabolic homeostasis via regulating SIRT4

Regulation of autophagy and apoptosis by Dp44mT-mediated activation of AMPK in pancreatic cancer cells

The Amplified Cancer Gene Laptm4b Plays A Critical Role In Autophagosome Maturation And Promotes Cancer Cell Survival During Metabolic Stress

LAPTM4B Facilitates Tumor Growth and Induces Autophagy in Hepatocellular Carcinoma

A novel ATG4B antagonist inhibits autophagy and has a negative impact on osteosarcoma tumors.

UBL 4 A Inhibits Autophagy-Mediated Proliferation and Metastasis of Pancreatic Ductal Adenocarcinoma Via Targeting LAMP 1

New Anti-Cancer Strategy to Suppress Colorectal Cancer Growth Through Inhibition of ATG4B and Lysosome Function

ITRAQ-based Bioinformatics Analysis Reveals the Potential Anticancer Effects of ATP4B in Gastric Cancer

Targeting STK26 and ATG4B: Mir-22-3p As a Modulator of Autophagy and Tumor Progression in HCC